803 related articles for article (PubMed ID: 26261009)
1. Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy.
Lammers WJ; Hirschfield GM; Corpechot C; Nevens F; Lindor KD; Janssen HL; Floreani A; Ponsioen CY; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Burroughs AK; Mason AL; Kowdley KV; Kumagi T; Harms MH; Trivedi PJ; Poupon R; Cheung A; Lleo A; Caballeria L; Hansen BE; van Buuren HR;
Gastroenterology; 2015 Dec; 149(7):1804-1812.e4. PubMed ID: 26261009
[TBL] [Abstract][Full Text] [Related]
2. Validation of Risk Scoring Systems in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis.
Efe C; Taşçilar K; Henriksson I; Lytvyak E; Alalkim F; Trivedi H; Eren F; Eliasson J; Beretta-Piccoli BT; Fischer J; Calişkan AR; Chayanupatkul M; Coppo C; Ytting H; Purnak T; Muratori L; Werner M; Muratori P; Rorsman F; Önnerhag K; Günşar F; Nilsson E; Heurgué-Berlot A; Güzelbulut F; Demir N; Gönen C; Semela D; Aladağ M; Kiyici M; Schiano TD; Montano-Loza AJ; Berg T; Ozaslan E; Yoshida EM; Bonder A; Marschall HU; Wahlin S
Am J Gastroenterol; 2019 Jul; 114(7):1101-1108. PubMed ID: 31241547
[TBL] [Abstract][Full Text] [Related]
3. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
Trivedi PJ; Bruns T; Cheung A; Li KK; Kittler C; Kumagi T; Shah H; Corbett C; Al-Harthy N; Acarsu U; Coltescu C; Tripathi D; Stallmach A; Neuberger J; Janssen HL; Hirschfield GM
J Hepatol; 2014 Jun; 60(6):1249-58. PubMed ID: 24548531
[TBL] [Abstract][Full Text] [Related]
4. Influence factors and a predictive scoring model for measuring the biochemical response of primary biliary cholangitis to ursodeoxycholic acid treatment.
Chen J; Xue D; Gao F; Tao L; Li Y; Zhang Q; Wang R; Sun L; Yang X; Liu Y; Zhu B; Niu S; Wang X
Eur J Gastroenterol Hepatol; 2018 Nov; 30(11):1352-1360. PubMed ID: 29889683
[TBL] [Abstract][Full Text] [Related]
5. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.
Harms MH; Lammers WJ; Thorburn D; Corpechot C; Invernizzi P; Janssen HLA; Battezzati PM; Nevens F; Lindor KD; Floreani A; Ponsioen CY; Mayo MJ; Dalekos GN; Bruns T; Parés A; Mason AL; Verhelst X; Kowdley KV; Goet JC; Hirschfield GM; Hansen BE; van Buuren HR;
Am J Gastroenterol; 2018 Feb; 113(2):254-264. PubMed ID: 29231188
[TBL] [Abstract][Full Text] [Related]
6. Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients.
Lammert C; Juran BD; Schlicht E; Chan LL; Atkinson EJ; de Andrade M; Lazaridis KN
J Gastroenterol; 2014 Oct; 49(10):1414-20. PubMed ID: 24317935
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis.
Goet JC; Murillo Perez CF; Harms MH; Floreani A; Cazzagon N; Bruns T; Prechter F; Dalekos GN; Verhelst X; Gatselis NK; Lindor KD; Lammers WJ; Gulamhusein A; Reig A; Carbone M; Nevens F; Hirschfield GM; van der Meer AJ; van Buuren HR; Hansen BE; Parés A;
Am J Gastroenterol; 2021 Jul; 116(7):1514-1522. PubMed ID: 33941746
[TBL] [Abstract][Full Text] [Related]
8. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
[TBL] [Abstract][Full Text] [Related]
9. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis.
Cheung AC; Lammers WJ; Murillo Perez CF; van Buuren HR; Gulamhusein A; Trivedi PJ; Lazaridis KN; Ponsioen CY; Floreani A; Hirschfield GM; Corpechot C; Mayo MJ; Invernizzi P; Battezzati PM; Parés A; Nevens F; Thorburn D; Mason AL; Carbone M; Kowdley KV; Bruns T; Dalekos GN; Gatselis NK; Verhelst X; Lindor KD; Lleo A; Poupon R; Janssen HLA; Hansen BE;
Clin Gastroenterol Hepatol; 2019 Sep; 17(10):2076-2084.e2. PubMed ID: 30616022
[TBL] [Abstract][Full Text] [Related]
10. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
11. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.
Weinmann A; Sattler T; Unold HP; Grambihler A; Teufel A; Koch S; Schuchmann M; Biesterfeld S; Wörns MA; Galle PR; Schulze-Bergkamen H
J Clin Gastroenterol; 2015; 49(5):438-47. PubMed ID: 25014239
[TBL] [Abstract][Full Text] [Related]
12. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis.
Harms MH; van Buuren HR; Corpechot C; Thorburn D; Janssen HLA; Lindor KD; Hirschfield GM; Parés A; Floreani A; Mayo MJ; Invernizzi P; Battezzati PM; Nevens F; Ponsioen CY; Mason AL; Kowdley KV; Lammers WJ; Hansen BE; van der Meer AJ
J Hepatol; 2019 Aug; 71(2):357-365. PubMed ID: 30980847
[TBL] [Abstract][Full Text] [Related]
13. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.
Corpechot C; Chazouillères O; Poupon R
J Hepatol; 2011 Dec; 55(6):1361-7. PubMed ID: 21703194
[TBL] [Abstract][Full Text] [Related]
14. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.
Lammers WJ; van Buuren HR; Hirschfield GM; Janssen HL; Invernizzi P; Mason AL; Ponsioen CY; Floreani A; Corpechot C; Mayo MJ; Battezzati PM; Parés A; Nevens F; Burroughs AK; Kowdley KV; Trivedi PJ; Kumagi T; Cheung A; Lleo A; Imam MH; Boonstra K; Cazzagon N; Franceschet I; Poupon R; Caballeria L; Pieri G; Kanwar PS; Lindor KD; Hansen BE;
Gastroenterology; 2014 Dec; 147(6):1338-49.e5; quiz e15. PubMed ID: 25160979
[TBL] [Abstract][Full Text] [Related]
15. Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis.
van Buuren HR; Lammers WJ; Harms MH; Hansen BE
Dig Dis; 2015; 33 Suppl 2():118-24. PubMed ID: 26642225
[TBL] [Abstract][Full Text] [Related]
16. Biochemical response to ursodeoxycholic acid among PBC patients: a nationwide population-based study.
Örnolfsson KT; Lund SH; Olafsson S; Bergmann OM; Björnsson ES
Scand J Gastroenterol; 2019 May; 54(5):609-616. PubMed ID: 31074667
[No Abstract] [Full Text] [Related]
17. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.
Chen S; Duan W; Li M; Li S; Lv T; Tian Q; Wang Q; Wu X; Zhao X; Wang X; Wang Y; Kong Y; Ma H; Ou X; You H; Jia J
J Gastroenterol Hepatol; 2019 Jul; 34(7):1236-1241. PubMed ID: 30365184
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis.
Shi TY; Zhang LN; Chen H; Wang L; Shen M; Zhang X; Zhang FC
World J Gastroenterol; 2013 Feb; 19(7):1111-8. PubMed ID: 23467321
[TBL] [Abstract][Full Text] [Related]
19. Ursodeoxycholic Acid Therapy in Patients with Primary Biliary Cholangitis with Limited Liver Transplantation Availability.
Melchor-Mendoza YK; Martínez-Benítez B; Mina-Hawat A; Rodríguez-Leal G; Duque X; Moran-Villota S
Ann Hepatol; 2017; 16(3):430-435. PubMed ID: 28425413
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
